Plaque Psoriasis
📧 Sign up to get email alerts when something new happens for Plaque Psoriasis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2018-03-14Clinical Trial Update: Safety of FURESTEM-CD Inj. in Patients With Moderate to Severe Plaque-type Psoriasis [Phase 1]
Phase 1 trial evaluating the safety of FURESTEM-CD injections in adults with moderate to severe plaque psoriasis.
-
CLINICAL_TRIALS trial_result · 2018-03-05Clinical Trial Update: Apremilast in Combination With Clobetasol Spray for the Treatment of Plaque Psoriasis [Phase 4]
This ClinicalTrials.gov entry provides an update on a Phase 4 trial evaluating apremilast in combination with clobetasol spray for plaque ps…
-
CLINICAL_TRIALS trial_result · 2018-02-28Clinical Trial Update: A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis [Phase 3]
Phase 3 trial update for ixekizumab in moderate-to-severe plaque psoriasis; study completed with results posted in 2018.
-
CLINICAL_TRIALS trial_result · 2018-02-13Clinical Trial Update: Efficacy and Safety of Prurisol Administered Orally for Active Moderate to Severe Chronic Plaque Psoriasis [Phase 2]
Phase 2 trial update on oral Prurisol for active moderate to severe chronic plaque psoriasis reports efficacy and safety results.
-
FDA approval · 2018-01-30FDA Approved: CLOBETASOL PROPIONATE — Original Application (Lupin Pharmaceuticals, Inc.)
FDA approved Lupin Pharmaceuticals' generic clobetasol propionate topical as an Original Application (ANDA). It is indicated for inflammator…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2018-01-26FDA Approved: SILIQ — Supplemental Application (Bausch Health US LLC)
The FDA approved a supplemental application for SILIQ (brodalumab) submitted by Bausch Health US LLC.
-
FDA approval · 2017-12-22FDA Approved: TAZAROTENE — Original Application (Mayne Pharma)
FDA approved Mayne Pharma's original ANDA for tazarotene, enabling the generic topical retinoid product to enter the market.
-
CLINICAL_TRIALS withdrawal · 2017-12-07Clinical Trial Update: GSK2894512 Vehicle-Controlled Study for Adult Plaque Psoriasis [Phase 3]
The Phase 3 vehicle-controlled study of GSK2894512 for adult plaque psoriasis has been withdrawn.
-
FDA approval · 2017-12-01FDA Approved: TALTZ — Supplemental Application (Eli Lilly and Company)
FDA approved a supplemental application for TALTZ (ixekizumab) submitted by Eli Lilly and Company, resulting in an expanded label for additi…
-
CLINICAL_TRIALS trial_result · 2017-11-13Clinical Trial Update: Trial of IMO-3100 in Patients With Moderate to Severe Plaque Psoriasis [Phase 2]
Phase 2 trial of IMO-3100 in moderate to severe plaque psoriasis completed with posted results.
-
CLINICAL_TRIALS trial_result · 2017-10-30Clinical Trial Update: Study on the Therapeutic Mechanisms of Dithranol Treatment in Patients With Chronic Plaque Psoriasis
The document reports on a completed clinical trial investigating the therapeutic mechanisms of dithranol (anthralin) in patients with chroni…
-
FDA approval · 2017-10-25FDA Approved: CLOBETASOL PROPIONATE — Original Application (Macleods Pharmaceuticals Limited)
FDA approved the original abbreviated new drug application for clobetasol propionate from Macleods Pharmaceuticals Limited.
-
CLINICAL_TRIALS trial_result · 2017-10-19Clinical Trial Update: Real-life Evaluation of the Daivobet® Gel Applicator
The document reports a completed real-world evaluation of the Daivobet Gel applicator for treating plaque psoriasis. It lists LEO Pharma as …
-
CLINICAL_TRIALS trial_result · 2017-10-04Clinical Trial Update: Effectiveness of Adalimumab in Moderate to Severe Plaque Psoriasis Patients With Distinct Co-morbidities
A completed clinical trial investigated the effectiveness of adalimumab in adults with moderate to severe plaque psoriasis, including patien…
-
FDA approval · 2017-09-22FDA Approved: CLOBETASOL PROPIONATE — Original Application (Lupin Pharmaceuticals, Inc.)
FDA approved Lupin Pharmaceuticals' original application for clobetasol propionate as a generic topical corticosteroid.
-
CLINICAL_TRIALS trial_result · 2017-09-20Clinical Trial Update: Trial of CF101 to Treat Patients With Psoriasis [Phase 2, Phase 3]
Phase 2/3 clinical trial for CF101 in plaque psoriasis has completed with results posted.
-
CLINICAL_TRIALS research · 2017-08-03Clinical Trial Update: Observational Study to Estimate the Effectiveness of Biologics When Treating Plaque Psoriasis
An observational study sponsored by AstraZeneca to estimate the effectiveness of biologic therapies for treating plaque psoriasis. The study…
-
CLINICAL_TRIALS trial_result · 2017-08-02Clinical Trial Update: A Study to Evaluate CNTO 1959 in the Treatment of Patients With Moderate to Severe Plaque-type Psoriasis [Phase 2]
Phase 2 clinical trial evaluating CNTO 1959 in adults with moderate to severe plaque-type psoriasis has completed and results have been post…
-
CLINICAL_TRIALS trial_result · 2017-08-01Clinical Trial Update: Clinical Trial of PSORI-CM01（YXBCM01） Granule to Treat Stable Plaque Psoriasis [NA]
The clinical trial evaluating PSORI-CM01 (YXBCM01) Granule for stable plaque psoriasis was terminated.
-
CLINICAL_TRIALS trial_result · 2017-07-21Clinical Trial Update: Efficacy of Secukinumab Compared to Ustekinumab in Patients With Plaque-type Psoriasis [Phase 3]
Phase 3 trial comparing the efficacy of Secukinumab versus Ustekinumab in patients with chronic plaque psoriasis has completed with results …
-
CLINICAL_TRIALS trial_result · 2017-07-19Clinical Trial Update: Efficacy and Safety of Prurisol Administered Orally for Active Mild to Moderate Chronic Plaque Psoriasis [Phase 2]
Phase 2 trial evaluating oral Prurisol for active mild-to-moderate plaque psoriasis reports efficacy and safety data, with the study complet…
-
CLINICAL_TRIALS trial_result · 2017-07-17Clinical Trial Update: A Study of Guselkumab in Participants With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab [Phase 3]
Phase 3 trial assessing guselkumab in moderate-to-severe plaque psoriasis patients with inadequate response to ustekinumab; study completed …
-
FDA approval · 2017-07-13FDA Approved: TREMFYA — Original Application (Janssen Biotech, Inc.)
The FDA approved TREMFYA (guselkumab) from Janssen Biotech as the original application for the treatment of moderate to severe plaque psoria…
-
CLINICAL_TRIALS trial_result · 2017-07-11Clinical Trial Update: Patient Preference of Taclonex Ointment to Taclonex Scalp Suspension in Adult Subjects With Psoriasis Vulgaris [Phase 4]
Phase 4 trial comparing patient preference between Taclonex Ointment and Taclonex Scalp Suspension in adults with plaque psoriasis; results …
-
CLINICAL_TRIALS trial_result · 2017-07-07Clinical Trial Update: A Study to Evaluate Safety and Efficacy of Toreforant (JNJ-38518168) in Participants With Moderate to Severe Plaque-type Psoriasis [Phase 2]
A Phase 2 trial evaluating the safety and efficacy of Toreforant (JNJ-38518168) in participants with moderate-to-severe plaque-type psoriasi…